RU2016137119A - Птичьи вирусные вакцины, которые являются стабильными в жидкой среде - Google Patents
Птичьи вирусные вакцины, которые являются стабильными в жидкой среде Download PDFInfo
- Publication number
- RU2016137119A RU2016137119A RU2016137119A RU2016137119A RU2016137119A RU 2016137119 A RU2016137119 A RU 2016137119A RU 2016137119 A RU2016137119 A RU 2016137119A RU 2016137119 A RU2016137119 A RU 2016137119A RU 2016137119 A RU2016137119 A RU 2016137119A
- Authority
- RU
- Russia
- Prior art keywords
- virus
- liquid
- paragraphs
- vaccine according
- sugar alcohol
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims 20
- 229960004854 viral vaccine Drugs 0.000 title 1
- 229960005486 vaccine Drugs 0.000 claims 19
- 241000700605 Viruses Species 0.000 claims 11
- 150000005846 sugar alcohols Chemical class 0.000 claims 10
- 241000271566 Aves Species 0.000 claims 8
- 230000002238 attenuated effect Effects 0.000 claims 8
- 241000711450 Infectious bronchitis virus Species 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 3
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- 241000702626 Infectious bursal disease virus Species 0.000 claims 1
- 241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (15)
1. Жидкая стабильная вакцина, которая содержит живой птичий вирус, 5-40% (масс./об.) сахарного спирта, и от 0,15 до 0,75 M аминокислоты, выбранной из группы, состоящей из аргинина, глутаминовой кислоты и глицина; где жидкая стабильная вакцина имеет pH от 6,0 до 8,0; где живой птичий вирус выбран из группы, состоящей из аттенуированного вируса, рекомбинантного птичьего вирусного вектора и рекомбинантного вирусного вектора аттенуированного птичьего вируса; и где рекомбинантный птичий вирусный вектор или рекомбинантный вирусный вектор аттенуированного птичьего вируса может дополнительно кодировать гетерологичный антиген.
2. Жидкая стабильная вакцина по п.1, где сахарным спиртом является сорбит.
3. Жидкая стабильная вакцина по пп. 1 и 2, где аминокислотой является аргинин.
4. Жидкая стабильная вакцина по любому из пп. 1-3, где количество сахарного спирта составляет 10-30% (масс./об.).
5. Жидкая стабильная вакцина по любому из пп. 1-4, где живой аттенуированный птичий вирус выбран из группы, состоящей из вируса инфекционного бронхита (IBV), вируса инфекционного бурсита (IBDV), вируса болезни Ньюкасла (NDV), вируса болезни Марека (MDV) и вируса герпеса индеек (HVT).
6. Жидкая стабильная вакцина по любому из пп. 1-5, дополнительно содержащая сахарную добавку, которая является несахарным спиртом, где общее количество сахарного спирта и несахарного спирта в жидкой стабильной вакцине составляет 15-40% (масс./об.).
7. Жидкая стабильная вакцина по любому из пп. 1-6, где общее количество сахарного спирта и несахарного спирта в жидкой стабильной вакцине составляет 25-40% (масс./об.).
8. Жидкая стабильная вакцина по пп. 6 и 7, где несахарный спирт выбран из группы, состоящей из сахарозы и трегалозы.
9. Жидкая стабильная вакцина по любому из пп. 1-8, которая дополнительно содержит буфер.
10. Жидкая стабильная вакцина по любому из пп. 1-9, где живым аттенуированным вирусом является IBV.
11. Жидкая стабильная вакцина по любому из пп. 1-10, которая дополнительно содержит живой аттенуированный MDV или рекомбинантный аттенуированный MDV вектор, который кодирует гетерологичный антиген.
12. Жидкая стабильная вакцина по любому из пп. 1-11, которая дополнительно содержит убитый птичий вирус.
13. Жидкая стабильная вакцина по любому из пп. 1-12, которая дополнительно содержит бактерию.
14. Способ содействия защите птиц против вируса инфекционного бронхита (IBV), включающий введение птице жидкой стабильной вакцины по любому из пп. 1-13.
15. Способ получения жидкой стабильной вакцины по любому из пп. 1-12, который включает комбинирование терапевтически эффективного количества живого аттенуированного птичьего вируса с 5-40% (масс./об.) сахарного спирта и от 0,15 до 0,75 M аминокислоты, выбранной из группы аргинина, глутаминовой кислоты и глицина; где жидкая стабильная вакцина имеет pH от 6,0 до 8,0.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940627P | 2014-02-17 | 2014-02-17 | |
| US61/940,627 | 2014-02-17 | ||
| PCT/EP2015/053188 WO2015121463A2 (en) | 2014-02-17 | 2015-02-16 | Poultry virus vaccines that are liquid stable |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016137119A true RU2016137119A (ru) | 2018-03-22 |
| RU2016137119A3 RU2016137119A3 (ru) | 2018-10-04 |
Family
ID=52473917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016137119A RU2016137119A (ru) | 2014-02-17 | 2015-02-16 | Птичьи вирусные вакцины, которые являются стабильными в жидкой среде |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9827305B2 (ru) |
| EP (1) | EP3107571B1 (ru) |
| JP (1) | JP2017505807A (ru) |
| CN (1) | CN105992593B (ru) |
| AR (1) | AR099470A1 (ru) |
| MX (1) | MX2016010651A (ru) |
| RU (1) | RU2016137119A (ru) |
| WO (1) | WO2015121463A2 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2844767C1 (ru) * | 2020-09-22 | 2025-08-06 | Юниверсити Оф Джорджия Рисёрч Фаундейшн, Инк. | Аттенуированный изолят штамма dmv1639 вируса инфекционного бронхита |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
| US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| AR099470A1 (es) | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
| TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
| EP3236881B1 (en) * | 2014-12-22 | 2021-04-14 | The University Of Georgia Research Foundation, Inc. | System for fowl vaccination |
| CN105999281B (zh) * | 2016-07-26 | 2019-02-19 | 河南后羿生物工程股份有限公司 | 禽类活病毒用冻干保护剂、制备方法及应用 |
| BR112019025019A2 (pt) * | 2017-05-31 | 2020-06-30 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | polipeptídeo isolado de pilus de clostridium perfringens, polipeptídeo imunogênico, vetor, vacina, uso de um polipeptídeo imunogênico, método de tratamento, anticorpo, método para detectar infecção e método para detectar um polipeptídeo imunogênico |
| AR113996A1 (es) | 2017-12-22 | 2020-07-08 | Intervet Int Bv | Vacunas líquidas de virus envueltos vivos |
| JP7619957B2 (ja) * | 2019-03-29 | 2025-01-22 | インターベット インターナショナル ベー． フェー． | 液体組成物中の生モリクテス綱細菌の安定化 |
| EP3980058A1 (en) | 2019-06-10 | 2022-04-13 | Boehringer Ingelheim Animal Health USA Inc. | Stabilized liquid live vaccine |
| JP2022547975A (ja) * | 2019-09-11 | 2022-11-16 | ゾエティス・サービシーズ・エルエルシー | 鳥病原体の抗原を発現する組換えシチメンチョウヘルペスウイルスベクターおよびそれらの使用 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| AR127944A1 (es) | 2021-12-23 | 2024-03-13 | Intervet Int Bv | Vacunas líquidas estabilizadas de virus vivos |
| CN116270500B (zh) * | 2021-12-30 | 2025-05-06 | 安徽贝金基因科技有限公司 | 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155589A (en) | 1958-04-14 | 1964-11-03 | Upjohn Co | Parenteral extravascular injectable vaccines for simultaneous immunization of canidae against rabies, canine distemper, and infectious canine hepatitis |
| US3526696A (en) | 1968-02-14 | 1970-09-01 | Lilly Co Eli | Shipping fever vaccine |
| GB1575155A (en) | 1978-04-11 | 1980-09-17 | Merck & Co Inc | Vaccine stabilizer |
| PT71926B (en) * | 1979-10-29 | 1982-03-31 | Merck & Co Inc | Process for preparing a liquid vaccine comprising a stabilizer |
| US4337242A (en) | 1980-02-05 | 1982-06-29 | Merck & Co., Inc. | Vaccine stabilizer containing L-glutamic acid and L-arginine |
| JPS589688A (ja) | 1981-07-06 | 1983-01-20 | Toyobo Co Ltd | 安定な酵素組成物 |
| JPS6153227A (ja) | 1984-08-23 | 1986-03-17 | Biseibutsu Kagaku Kenkyusho:Kk | 日本脳炎・豚パルボウイルス感染症混合生ワクチン |
| US4867975A (en) * | 1988-01-27 | 1989-09-19 | University Of Delaware | Live attenuated temperature-sensitive avian infectious bronchitis virus vaccines and preparation and use thereof |
| CA2075521C (en) | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
| US5443959A (en) | 1992-09-09 | 1995-08-22 | Tokuyama Corporation | Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof |
| EP0650734B1 (en) | 1993-10-28 | 1999-03-10 | Division Of Microbiology, Kyoto Biken Laboratories, Inc. | Pentavalent live viral vaccine |
| FR2719479B1 (fr) | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
| US5593824A (en) | 1994-09-02 | 1997-01-14 | Pharmacia Biotech, Inc. | Biological reagent spheres |
| US5565318A (en) | 1994-09-02 | 1996-10-15 | Pharmacia Biotech, Inc. | Room temperature stable reagent semi-spheres |
| FR2742756B1 (fr) | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
| US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| NZ503463A (en) | 1997-09-25 | 2002-10-25 | Biotechnology Res & Dev | Leukotoxin deletion mutant of Pasteurella haemolytica |
| CN1053590C (zh) | 1998-10-19 | 2000-06-21 | 卫生部长春生物制品研究所 | 冻干甲型肝炎减毒活疫苗及其保护剂 |
| EP1336410A4 (en) | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
| CA2482448C (en) | 2002-04-11 | 2014-07-08 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| JP2006501237A (ja) | 2002-08-26 | 2006-01-12 | ファイザー・プロダクツ・インク | 家畜の呼吸系と生殖系の感染症に対するワクチン |
| US6931888B2 (en) | 2003-02-07 | 2005-08-23 | Ferro Corporation | Lyophilization method and apparatus for producing particles |
| AU2004263813B8 (en) | 2003-02-25 | 2008-09-11 | Medimmune, Llc | Methods of producing influenza vaccine compositions |
| ATE347373T1 (de) | 2003-07-02 | 2006-12-15 | Biotechnology Res & Dev | Akapsuläre i p. multocida hyae /i deletionsmutanten |
| WO2005052116A2 (en) | 2003-11-19 | 2005-06-09 | Merck & Co., Inc. | Preservative-containing virus formulations |
| MX2007005379A (es) * | 2004-11-05 | 2007-07-04 | Wellstat Biologics Corp | Formulaciones de virus envueltos estables y filtrables. |
| GB0503337D0 (en) | 2005-02-17 | 2005-03-23 | Glaxosmithkline Biolog Sa | Compositions |
| US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| US20070259348A1 (en) | 2005-05-03 | 2007-11-08 | Handylab, Inc. | Lyophilized pellets |
| ES2373238T3 (es) | 2005-09-16 | 2012-02-01 | Merial Ltd. | Estabilizadores para vacunas liofilizadas. |
| CN104984352A (zh) * | 2005-11-21 | 2015-10-21 | 圣诺菲·帕斯图尔有限公司 | 重组病毒的稳定制剂 |
| US20090274734A1 (en) | 2005-12-02 | 2009-11-05 | Stichting Katholieke Universiteit | Method for obtaining hollow particles |
| EP1981483A1 (en) | 2006-01-24 | 2008-10-22 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
| JP5179521B2 (ja) | 2007-03-05 | 2013-04-10 | カディラ・ヘルスケア・リミテッド | ペグ‐インターフェロンアルファ接合体および凍結保護剤としてラフィノースを含む組成物 |
| CN104998257A (zh) | 2007-04-06 | 2015-10-28 | 武田疫苗公司 | 用于活的减毒病毒的方法和组合物 |
| JP5307801B2 (ja) | 2007-05-18 | 2013-10-02 | メディミューン・エルエルシー | 凍結乾燥フォームによる生物活性材料の防腐 |
| SG182206A1 (en) | 2007-06-14 | 2012-07-30 | Univ Oklahoma State | Vaccines containing canine parvovirus genetic variants |
| TWI436789B (zh) | 2008-01-21 | 2014-05-11 | Intervet Int Bv | 含有藥學化合物的顆粒之冷凍乾燥方法及含有此顆粒的藥學包 |
| WO2009109550A1 (en) | 2008-03-05 | 2009-09-11 | Sanofi Pasteur | Process for stabilizing an adjuvant containing vaccine composition |
| EP2143440A1 (fr) | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| CN102202688B (zh) * | 2008-11-07 | 2017-04-12 | 印度血清研究所私人有限公司 | 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法 |
| US7998488B2 (en) | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
| US8980610B2 (en) | 2008-11-20 | 2015-03-17 | Biogen Idec Ma Inc. | Arginine inactivation of viruses |
| JP2012519471A (ja) | 2009-01-30 | 2012-08-30 | ザ・ボード・オブ・リージェンツ・フォー・オクラホマ・ステート・ユニバーシティ | 北米のイヌにおいて広まっているイヌジステンパーウイルスに基づく免疫原性組成物、ワクチンおよび診断法 |
| TWI471127B (zh) | 2009-04-29 | 2015-02-01 | Intervet Int Bv | 供人類使用之口服崩解錠劑的製備方法、所製得之口服崩解錠劑、以及含有該口服崩解錠劑的包裝物 |
| TWI468157B (zh) | 2009-04-29 | 2015-01-11 | Intervet Int Bv | 形成錠劑的方法，進行該方法的系統及包含該錠劑的包裝物 |
| US8557253B2 (en) | 2009-10-07 | 2013-10-15 | Sanofi Pasteur Sa | Stabilizing excipient for inactivated whole virus vaccine |
| JP5891175B2 (ja) | 2009-12-11 | 2016-03-22 | バインド セラピューティックス インコーポレイテッド | 治療用粒子の凍結乾燥に対する安定製剤 |
| UA117272C2 (uk) | 2011-02-17 | 2018-07-10 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Новий європейський штам prrsv |
| US20140017318A1 (en) | 2012-07-10 | 2014-01-16 | Kevin O'Connell | Method to produce a medicinal product comprising a biologically active protein and the resulting product |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| US9480739B2 (en) | 2013-03-15 | 2016-11-01 | Intervet Inc. | Bovine virus vaccines that are liquid stable |
| US9393298B2 (en) | 2013-03-15 | 2016-07-19 | Intervet Inc. | Liquid stable bovine virus vaccines |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| AR099470A1 (es) * | 2014-02-17 | 2016-07-27 | Intervet Int Bv | Vacunas de virus de aves de corral líquidas |
| TWI670085B (zh) | 2014-02-19 | 2019-09-01 | 荷蘭商英特威國際公司 | 液體穩定之豬病毒疫苗 |
-
2015
- 2015-02-13 AR ARP150100451A patent/AR099470A1/es unknown
- 2015-02-16 US US15/119,014 patent/US9827305B2/en active Active
- 2015-02-16 EP EP15704792.9A patent/EP3107571B1/en active Active
- 2015-02-16 MX MX2016010651A patent/MX2016010651A/es unknown
- 2015-02-16 RU RU2016137119A patent/RU2016137119A/ru not_active Application Discontinuation
- 2015-02-16 JP JP2016552337A patent/JP2017505807A/ja active Pending
- 2015-02-16 WO PCT/EP2015/053188 patent/WO2015121463A2/en not_active Ceased
- 2015-02-16 CN CN201580008951.6A patent/CN105992593B/zh active Active
-
2017
- 2017-10-20 US US15/789,462 patent/US20180104328A1/en not_active Abandoned
-
2018
- 2018-09-14 US US16/131,486 patent/US20190008950A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2844767C1 (ru) * | 2020-09-22 | 2025-08-06 | Юниверсити Оф Джорджия Рисёрч Фаундейшн, Инк. | Аттенуированный изолят штамма dmv1639 вируса инфекционного бронхита |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015121463A2 (en) | 2015-08-20 |
| CN105992593B (zh) | 2020-03-06 |
| JP2017505807A (ja) | 2017-02-23 |
| AR099470A1 (es) | 2016-07-27 |
| EP3107571A2 (en) | 2016-12-28 |
| WO2015121463A3 (en) | 2015-10-08 |
| EP3107571B1 (en) | 2019-04-03 |
| CN105992593A (zh) | 2016-10-05 |
| US20190008950A1 (en) | 2019-01-10 |
| US9827305B2 (en) | 2017-11-28 |
| US20180104328A1 (en) | 2018-04-19 |
| US20160346381A1 (en) | 2016-12-01 |
| MX2016010651A (es) | 2016-11-08 |
| RU2016137119A3 (ru) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016137119A (ru) | Птичьи вирусные вакцины, которые являются стабильными в жидкой среде | |
| Hein et al. | Review of poultry recombinant vector vaccines | |
| Baron et al. | Recent advances in viral vectors in veterinary vaccinology | |
| Mahgoub | An overview of infectious bursal disease | |
| RU2018116857A (ru) | Мультивалентные рекомбинантные вирусы птичьего герпеса и вакцины для иммунизации птиц | |
| ES2574827T3 (es) | Líneas de embriocitoblastos de pato para la producción de vacunas antivíricas | |
| PE20141482A1 (es) | Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos | |
| Faulkner et al. | Passive antibody transfer in chickens to model maternal antibody after avian influenza vaccination | |
| RU2020123713A (ru) | Жидкие вакцины на основе живых оболочечных вирусов | |
| PH12020552009A1 (en) | Antigen variant of varicella zoster virus and use thereof | |
| RU2018130813A (ru) | Вакцины против fmdv на основе рекомбинантного аденовирусного вектора и их применение | |
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| RU2015109724A (ru) | Жидкие стабильные вирусные вакцины | |
| RU2014120471A (ru) | Конструкции рекомбинантного непатогенного вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса болезни ньюкасла | |
| RU2011104201A (ru) | Вакцины против инфекционного бронхита, полученные из ib-qх-подобных штаммов | |
| RU2019102170A (ru) | Вирус утиного энтерита и его применение | |
| RU2018103145A (ru) | Вирус утиного энтерита и его применение | |
| Umar et al. | Emerging threat of H9N2 viruses in poultry of Pakistan and vaccination strategy | |
| Li et al. | Protective efficacy of an H5N1 DNA vaccine against challenge with a lethal H5N1 virus in quail | |
| PE20170429A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| Ganapathy et al. | Pros and cons on use of live viral vaccines in commercial chicken flocks | |
| RU2016106419A (ru) | Усиление иммунного ответа птиц, индуцированного вирусным вектором | |
| RU2014146772A (ru) | Новые ротавирусные вакцинные композиции и способ получения вышеуказанных композиций | |
| RU2017130233A (ru) | Рекомбинантные вирусы mdv1 и их применение | |
| Röhrs et al. | A model for early onset of protection against lethal challenge with highly pathogenic H5N1 influenza virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190326 |